Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Daniel M Schmitt is President, CEO and Director at Actuate Therapeutics. OQRO lists 9 transactions filed with the SEC under this name, the latest on Oct 29, 2026, each linked to the official Form 4.
President, CEO and Director
Disclosures on record
9
Companies involved
1
1 purchase disclosed. $1,000 placed after each of the 1 purchases disclosed since 2025-11-14 would be worth $851 today ($1K put in); the same in the S&P 500 (SPY): $998.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Actuate TherapeuticsACTU
9 disclosures · Feb 2026 – Oct 2026 · 1 bought
Oct 28, 2026Bought~$50Kdisclosed Oct 29
DetailsOfficial recordOct 28, 202670Kdisclosed Oct 29
DetailsAug 14, 2026272Kdisclosed Aug 15
DetailsOfficial recordAug 14, 2026272Kdisclosed Aug 15
DetailsOfficial recordAug 14, 2026121Kdisclosed Aug 15
DetailsOfficial recordApr 1, 2026237Kdisclosed Apr 2
DetailsOfficial recordFeb 13, 2026272Kdisclosed Feb 14
DetailsOfficial recordFeb 13, 2026272Kdisclosed Feb 14
DetailsOfficial recordFeb 13, 2026122Kdisclosed Feb 14
DetailsOfficial recordAs of the latest filing on , Daniel M Schmitt reported holding 442,560 shares of Actuate Therapeutics (ACTU), worth about $126K at the last close of $0 (Nov 13, 2026). In the last 12 months, Daniel M Schmitt bought $50K in 1 open-market purchase.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Actuate Therapeutics ACTU | 442,560 | 443K direct | $0 | $126K | Oct 28, 2026 |
Is this Daniel M Schmitt’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Daniel M Schmitt bought shares on the open market in 2026.
Daniel M Schmitt reported 1 open-market purchase and 0 sales since 2026; purchases in 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $50K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Daniel M Schmitt reported 1 open-market purchase and 0 sales here, 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
On the latest SEC Form 4, dated Oct 28, 2026, Daniel M Schmitt reported holding 442,560 shares of Actuate Therapeutics (ACTU). At the last close of $0 on Nov 13, 2026, that is about $126K. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Daniel M Schmitt reported 1 open-market purchase worth $50K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Daniel M Schmitt bought shares on the open market in 2026.
In SEC filings since 2026: the latest open-market purchase is from 2026; no open-market sale is on record.
Actuate Therapeutics (ACTU), from 2026 to 2026: 1 purchase and 0 sales.
